Release test results
99.736%HPLC purity · meets ≥ 99.5% spec
Mass-spec identityConfirmed · 10.08 mg
Related impurities (total)0.264%
Endotoxin<1.0 EU/mg
HPLC retention time9.43 min
MethodHPLC + LC-MS
ResultPass · meets spec
Lot record
CompoundTesamorelin
Presentation10 MG
Lot numberRGX-26-TESAMORELIN-754
COA numberNS-2026-05167
Test date14 Apr 2026
Release date17 Apr 2026
Independent labNordicstar Labs
StatusSuperseded
Tesamorelin — lot history
| Lot | Presentation | Tested | HPLC purity | Status |
|---|---|---|---|---|
| RGX-26-TESAMORELIN-1046 | 10 MG | Jul 16, 2026 | 99.753% | Current |
| RGX-26-TESAMORELIN-1047 | 20 MG | Jul 15, 2026 | 99.584% | Current |
| RGX-26-TESAMORELIN-754 this lot | 10 MG | Apr 14, 2026 | 99.736% | Superseded |
| RGX-26-TESAMORELIN-753 | 20 MG | Apr 7, 2026 | 99.646% | Superseded |
| RGX-26-TESAMORELIN-654 | 10 MG | Jan 7, 2026 | 99.684% | Superseded |
| RGX-25-TESAMORELIN-653 | 20 MG | Dec 28, 2025 | 99.667% | Superseded |
!
Research use only
This lot record documents a research compound sold for laboratory use only — not for human or animal consumption. Results are as tested by Nordicstar Labs; retained samples are archived for five years. Research Use Agreement →